InvestSMART

Imugene Limited (ASX:IMU)

ALERT: Price-sensitive ASX Announcement for IMU
Current share price for IMU : $0.070 -0.013 (-15.66%)+
Announcement
Release
31 Jul 2026 9:12AM
Price at Release
$0.083
Full Release
download
Summary
Imugene Limited, a clinical-stage cellular therapy company, reported its quarterly activities and financial results for the period ending 30 June 2026. The company achieved significant clinical milestones with its azer-cel therapy, receiving FDA Fast Track Designation for additional indications and presenting promising trial results at the ASCO Annual Meeting. Financially, Imugene completed a $16 million capital raise, while managing its cash flow with $2.510 million in cash equivalents by quarter-end. The company is implementing cost-cutting measures and has secured an additional $11.12 million from investors post-quarter to support ongoing clinical developments and business objectives.
Key Points
  • Imugene Limited reported significant clinical progress with its azer-cel therapy in Phase 1b trials.
  • FDA granted Fast Track Designation for azer-cel in additional indications: CLL/SLL and MZL.
  • The company completed a capital raise of $16 million through institutional placement and SPP.
  • Net cash used in operating activities for the quarter was $9.211 million with R&D expenses totaling $4.261 million.
  • Imugene's cash and cash equivalents at the end of June 2026 were $2.510 million.
  • Imugene plans to streamline its R&D program and implement cost-cutting measures to manage cash flow.
  • The company raised $11.12 million post quarter from a placement with investors.
  • Clinical trials for azer-cel were ongoing across ten US and five Australian sites.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.